XML 44 R25.htm IDEA: XBRL DOCUMENT v3.25.0.1
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
SCHEDULE OF DISAGGREGATED REVENUE

For the years ended December 31, 2024 and 2023, the Company had the following disaggregated revenue:

  

   Year Ended December 31, 
   2024   %   2023   % 
                 
Telehealth product revenue  $83,423,428    40%  $88,886,664    58%
Telehealth subscription revenue   70,015,203    33%   4,266,255    3%
WorkSimpli revenue   54,015,207    25%   54,394,087    36%
Medifast collaboration revenue   5,000,000    2%   5,000,000    3%
Total net revenue  $212,453,838    100%  $152,547,006    100%
SCHEDULE OF CONTRACT WITH CUSTOMER LIABILITY

The following table summarizes deferred revenue activities for the periods presented:

  

       
   Year Ended December 31, 
   2024   2023 
Beginning of period  $8,828,598   $5,547,506 
Additions   214,304,407    58,319,435 
Revenue recognized   (208,652,088)   (55,038,343)
End of period  $14,480,917   $8,828,598 
SCHEDULE OF ACCOUNTS RECEIVABLE

The Company’s accounts receivable balances are as follows for each of the periods presented:

SCHEDULE OF ACCOUNTS RECEIVABLE 

 

   2024  2023
   Year Ended December 31,
   2024  2023
Beginning of period  $5,277,250   $2,834,750 
End of period  $8,217,813   $5,277,250 
SUMMARY OF INVENTORY

As of December 31, 2024 and 2023, the Company’s inventory consisted of the following:

  

       
   December 31, 
   2024   2023 
         
Finished goods  $1,554,600   $1,898,784 
Raw materials and packaging components   1,506,078    1,216,833 
Inventory reserve   (263,320)   (355,685)
Total inventory, net  $2,797,358   $2,759,932 
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES

The following table summarizes the number of shares of common stock issuable pursuant to our convertible securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive even though the exercise price could be less than the average market price of the common shares:

  

       
   Year Ended December 31, 
   2024   2023 
         
RSUs and RSAs   3,157,706    3,556,375 
Stock options   1,288,000    2,336,222 
Warrants   1,743,730    4,730,607 
Convertible long-term debt   671,141    671,141 
Potentially dilutive securities   6,860,577    11,294,345